Skip to main content
TG THERAPEUTICS, INC. logo

TG THERAPEUTICS, INC. — Investor Relations & Filings

Ticker · TGTX ISIN · US88322Q1085 LEI · 529900X21UKABN9NJ529 US Manufacturing
Open in API
Filings indexed 1,012 across all filing types
Latest filing 2026-06-03 Regulatory Filings
Country US United States of America
Listing US TGTX

About TG THERAPEUTICS, INC.

https://www.tgtherapeutics.com/

TG Therapeutics, Inc. is a fully integrated, commercial-stage biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. The company's primary area of focus is autoimmune diseases, particularly multiple sclerosis (MS). Its lead commercial product is BRIUMVI® (ublituximab), an approved therapy for adults with relapsing forms of MS. TG Therapeutics also develops a pipeline of potential therapies for B-cell malignancies and other autoimmune conditions, including investigational CAR-T cell therapies.

Recent filings

Filing Released Lang Actions
FORM 8-K
Regulatory Filings Classification · 90% confidence The document is a Form 8-K “Current Report” filed with the SEC under Items 8.01 and 9.01, comprising a non‐financial press release regarding clinical trial data. It does not include actual financial statements or detailed financial data, nor is it an earnings release, management change notice, or a report attachment announcement. This is a regulatory compliance filing for disclosure of an “Other Event,” so it is best classified under the general Regulatory Filings category (RNS).
2026-06-03 English
FORM 8-K
Regulatory Filings Classification · 94% confidence The document is a Form 8-K “Current Report” filed with the SEC describing an item of corporate news (positive topline trial results) and attaching a press release as an exhibit. It does not contain financial statements or in-depth analysis, nor is it an earnings release, board change notice, dividend, or other specific filers; it is a general regulatory compliance filing. Therefore, it best matches the fallback category “Regulatory Filings” (RNS).
2026-05-27 English
8-K - TG THERAPEUTICS, INC. (0001001316) (Filer)
Earnings Release Classification · 12% confidence The document is a Form 8-K Current Report under Item 2.02 announcing the company’s press release on quarterly results (three months ended March 31, 2026). This is the initial public announcement of periodical financial results rather than a full interim report or transcript. It fits the definition of an Earnings Release (ER). Q1 2026
2026-05-06 English
8-K - TG THERAPEUTICS, INC. (0001001316) (Filer)
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce major events that shareholders should know about. The content describes the entry into a material definitive agreement related to a financing amendment, including details about a new term loan facility and its terms. It does not contain comprehensive financial statements or detailed financial performance data typical of Annual Reports (10-K) or Interim Reports (IR). It is not a transcript, proxy, or governance document. The focus is on a financing update, specifically the amendment and establishment of a new loan facility. Therefore, this filing fits best under Capital/Financing Update (CAP). The document length is over 6,000 characters and contains substantive detail about the financing terms, supporting this classification with high confidence.
2026-03-20 English
10-K - TG THERAPEUTICS, INC. (0001001316) (Filer)
Annual Report FY 2025
2026-02-27 English
8-K - TG THERAPEUTICS, INC. (0001001316) (Filer)
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated February 26, 2026, by TG Therapeutics, Inc. It announces the results of operations for the three and twelve months ended December 31, 2025, via a press release attached as Exhibit 99.1. The text explicitly states that the information is a press release and is being furnished, not filed as a full report. The document length is 3513 characters, which is relatively short and consistent with an announcement rather than a full financial report. The document does not contain detailed financial statements or substantive financial data itself, only a reference to the press release. According to the rules, such a document is best classified as an Earnings Release (ER) since it is the initial announcement of quarterly/periodical financial results (key highlights only).
2026-02-26 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.